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Introduction: Novel tobacco products require independent research to assess their safety. This 
study assessed the current literature for trials comparing levels of biomarkers of exposure 
(BoE) between conventional cigarettes and heat-not-burn (HNB) devices.  
Methods: Ten databases were searched using terms including: ‘heat not burn’, ‘iqos’, ‘teeps’, 
‘mrtp’, ‘tobacco heating’, and ‘glo’, between 1st January 2010 and 13th August 2019. 
Randomised controlled trials assessing comparative BoE levels in humans using either 
conventional cigarettes or novel HNB devices were eligible. BoE were tabulated, and 
differences between the intervention and control groups analysed and combined using a 
random effects meta-analysis. 
Results: Ten non-blinded, randomised controlled trials were eligible, involving a total of 1,766 
participants. Studies regularly reported on 12 BoE (including nicotine). HNB devices assessed 
included the ‘IQOS’ and ‘glo’ devices, and ‘precursor’ (being developed) HNB devices. In 
comparison to conventional cigarettes, all 12 BoEs assessed were significantly lower for 
participants assigned to a HNB device. In comparison to smoking abstinence, HNB devices 
were statistically equivalent for eight BoEs and significantly elevated for four BoEs. 
Conclusions: This review found that the potential for harm to humans is reduced when using 
HNB devices compared to conventional cigarettes, as indicated by significant reductions in 
BoE levels. Whilst these results support tobacco manufacturer claims of improved safety, the 
small number of studies included, limited range of BoE assessed, and involvement of the 
tobacco industry necessitate further independent research to confirm the HNB devices as being 




























This study supports claims made by tobacco manufacturers on the improved safety of heat-not-
burn tobacco devices in comparison to conventional cigarettes. These novel devices lead to 
reduced exposure to key biomarkers, which are linked to the health consequences attributed to 
tobacco use. This has strong implications for international public health as well as further 
research and policy development relating to the safety aspects and legalities of novel tobacco 
products. 
ABBREVIATIONS 
1-OHP  1-hydroxypyrene 
2-AN  2-aminoaphthalene 
3-HPMA 3-hydroxypropylmercaptapuric acid  
4-ABP  4-aminobiphenyl 
BAT  British American Tobacco 
BoE  Biomarker of Exposure 
CC  Conventional Cigarette  
CEMA  2-cyanoethylmercapturic acid 
CI  Confidence Interval 
COHb  Carboxyhemoglobin 
HNB  Heat-Not-Burn 
HPHC  Harmful and Potentially Harmful Constituents 
JBI  Joanna Briggs Institute 
MHBMA Monohydroxybutenyl-mercapturic Acid 
NNN  N-nitrosonornicotine 
NNAL  4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
o-tol   o-toluidine 
IQOS  I Quit Original Smoking 
PMI  Philip Morris International 
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
RCT  Randomised Controlled Trial 
S-PMA  S-phenylmercapturic acid 
SD  Standard Deviation 

























Tobacco use remains a leading preventable cause of morbidity and mortality and is linked to a 
growing array of health consequences, including lung cancer, chronic obstructive pulmonary 
disorder, and cardiovascular diseases.1,2 An individual’s risk of tobacco-attributable diseases is 
influenced by both their genetic predisposition and lifetime cumulative exposure to harmful 
tobacco product constituents, including through exposure to second and third-hand smoke.3,4 
Conventional cigarettes remain a primary method for the inhalation of tobacco smoke, which 
contain thousands of chemical constituents, many of which are known carcinogens. As global 
tobacco use is predicted to reach 1.5 billion smokers by 2050,5 the World Health Organization 
and other public health stakeholders have attempted to manage the tobacco epidemic through 
recommending comprehensive tobacco control policies. This includes prohibiting advertising, 
regulating tobacco product appearance, and implementing tax increases.6 However, tobacco 
manufacturers continue their attempts to circumvent these regulations, to ensure maintenance 
of the smoking culture, and recruitment of the ‘next generation’ of smokers.7-10 
One such method for attracting and retaining smokers is the development and marketing of 
‘heat-not-burn’ (HNB) devices, which can resemble either electronic or conventional cigarettes 
in appearance, and are promoted as ‘reduced-risk’ tobacco products.11 Unlike electronic 
cigarettes which utilise a nicotine-containing liquid or conventional cigarettes which achieve 
combustion by heating to at least 600ºC, these devices heat either a nicotine-free liquid which 
passes through tobacco leaf, or heat processed tobacco leaf to less than 350ºC. It is proposed 
that HNB devices are less harmful to human health than conventional cigarettes through 
reduced exposure to carcinogens and other toxic constituents.11,12 The earliest models of these 
HNB devices such as ‘Premier’, ‘Eclipse’ and ‘Accord’ were developed in the 1980s and 
1990s. However, several issues were cited by smokers, including difficult operation and poor 
























Following the poor uptake of these earlier models, emerging HNB devices include the ‘I Quit 
Original Smoking’ (IQOS; Philip Morris International [PMI]) and ‘glo’ (British American 
Tobacco [BAT]), which were first made available in Japan and Italy, though have rapidly 
spread to other countries.15  
If HNB devices are less harmful than conventional cigarettes, they could represent a method 
for harm reduction, by allowing individuals to continue smoking behaviours and satisfying 
their nicotine addiction, whilst causing less harm to themselves and others. Assessing toxicant 
exposure and estimating health risks associated with tobacco products can be achieved through 
determining the levels of biomarkers of exposure (BoE). These are measures of exposure to 
‘harmful and potentially harmful constituents’ (HPHC) within tobacco products. The Institute 
of Medicine of the US Academy of Science defines a BoE as "a tobacco constituent or 
metabolite that is measured in a biological fluid or tissue that has the potential to interact with 
a biological macromolecule; sometimes considered a measure of internal dose".16 BoE can 
therefore provide a more accurate assessment of health risk compared to the quantity of 
exposure (e.g. cigarettes per day), through utilising a range of variables (tobacco and disease-
related) which allows comparison of the relative harms of different tobacco products.16 
The concept of a risk continuum by McNeill and Munafò (2013) places conventional cigarettes 
at the high-risk end, nicotine replacement therapy at the low-risk end and HNB products at a 
to-be-determined point in between.17 Assessing the absolute risk of these devices is ongoing, 
with independent research required to guide relevant legislation and policy development. A 
recent (2018) independent review assessing the emissions, safety, and epidemiology of HNB 
products found that “switching from smoking cigarettes to using HNB significantly reduces but 
does not eliminate exposure to HPHC”.18 However, contradictory data released from PMI on 
their own IQOS device indicated there may be no significant difference in harm compared to 
























conventional cigarettes, and increasing public interest in these products,20 we conducted a 
systematic review and meta-analysis to explore the safety profiles of HNB devices compared 
to conventional cigarettes. The underlying aim for this review was to evaluate comparative 
BoE levels resulting from use of either conventional cigarettes versus novel HNB devices. 
METHODS 
This systematic review is reported according to the recommendations of the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.21  
Search strategy and study eligibility 
A systematic search strategy was used to identify original studies published in English between 
1st January 2010 and 13th August 2019. The date limit was set to ensure inclusion of articles 
relating to emerging HNB devices, such as ‘THS2.2’ (IQOS), and ‘THP1.0’ (glo), whilst 
excluding outdated precursor HNB devices such as ‘Eclipse’, ‘Accord’ and ‘Premier’. Ten 
databases were searched: CINAHL, Cochrane Library, EBSCO MegaFile Premier, EMBASE, 
Global Health, Medline, ProQuest, PsycINFO, Scopus, and Web of Science. General search 
terms included ‘tobacco heating’, ‘heat not burn’, ‘HNB’, ‘modified risk tobacco product’, and 
‘mrtp’, and device-specific terms such as ‘iqos’, ‘teeps’, and ‘glo’. A full search strategy 
detailing the search terms, dates, and databases used is available in Supplementary Appendix 
1. Citation and refer nce lists were scanned to identify additional eligible studies. 
Studies eligible for inclusion were those that investigated the safety of HNB products in 
humans through assessing BoE levels compared to conventional cigarettes. Studies that 
investigated BoE or other safety data on mice, rats, or in-vitro human tissue samples were 
ineligible, as we intended to collect BoE data that results directly from human exposure. 
Studies that assessed the safety of electronic cigarettes, or non-safety-related aspects of HNB 
























and conference abstracts. Titles of potentially eligible studies were initially scanned by a single 
author (AD), with the assessment of the remaining studies for eligibility being performed by 
three authors (AD, SS, TK). Abstracts were read by these authors, who independently cross-
checked each other’s lists of potentially eligible studies. Full-texts were then read to assess for 
final eligibility, with disagreements resolved by consensus.  
Data extraction and quality appraisal 
Two authors (AD and DB) were responsible for data extraction. Data items extracted were: 
author affiliations, source(s) of funding, year of publication, study type, country of participant 
recruitment, participant demographics (including smoking habits), intervention and control 
groups employed, participant numbers assigned to each group, duration of exposure to 
interventions, puffing topography, and biomarkers measured. The primary outcome of interest 
from these studies included differences in BoE levels after assignment to the intervention or 
control groups, and comparative BoE differences between these groups.  
Study quality was assessed by two authors (SS and TK) and checked by a third author (AD), 
with disagreements resolved by consensus. The Joanna Briggs Institute (JBI) critical appraisal 
checklist for randomised controlled trials was used to assess study quality.22 This validated 13-
item checklist assesses study quality based on the method of randomisation used, similarity in 
participant characteristics between groups, level of blinding amongst the involved parties 
(including participants, those delivering treatment, and assessors), appropriateness of statistical 
analysis, and sources of selection and analytical bias. Due to the strong links between the 
eligible studies and tobacco manufacturers (including author employment and the provision of 
funding), the authors of this review were careful in assessing the sources and significance of 
bias in eligible articles. This included assessing the clarity of the descriptions provided relating 
to the equal treatment of participant groups, the method of randomisation, outcome 
























they sufficiently addressed 11 of the 13 JBI checklist items, moderate quality if they addressed 
between 7 and 10 of the criteria, and low quality if they addressed 6 or fewer of the criteria.  
Data synthesis and analysis 
Each BoE was assessed individually and compared between the HNB, conventional cigarettes 
(CC) and abstinence (Abs) groups. Studies captured within this review all used a pre-post 
design with one or two control groups (CC and/or Abs). Standardised effect sizes (d) were 
therefore calculated according to the method recommended by Carlson and Schmidt,23  
𝑑 =
(𝑇𝑝𝑜𝑠𝑡 − 𝑇𝑝𝑟𝑒) − (𝐶𝑝𝑜𝑠𝑡 − 𝐶𝑝𝑟𝑒)
𝑆𝐷𝑝𝑟𝑒
 
where Tpost and Cpost are the post-intervention means of the outcome in treatment and 
comparison groups respectively, Tpre and Cpre are the corresponding pre-intervention means, 
and SDpre is the pooled standard deviation of the two groups at the pre-intervention time period. 
As d is a biased estimator with small sample sizes, we used the correction factor suggested by 
Hedges,24 where ni is the total sample size for the ith comparison (i.e. ni = nT + nC):  
𝐽 = 1 −
3
4 × (𝑛𝑖 − 1) − 1
 
The reported effect sizes (ES) are the product d x J, with variance given by the equation 
below, where ρ is the correlation between the pre- and post-measurements within a group:25 




𝑛𝑇 + 𝑛𝐶 − 2
𝑛𝑇 + 𝑛𝐶 − 4
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) − 𝑑2 
For trials where the means and standard deviations of the change (defined as post – pre) were 































This was then averaged as appropriate for the ith comparison. However, in many instances data 
on change was not available and we therefore imputed the average pre-post correlation from 
those trials which did report change. Sensitivity analyses were also conducted assuming 𝜌 =
0.1 and 𝜌 = 0.9 for all studies. After a standardised effect size and corresponding confidence 
interval was calculated for each study using the above, the overall effect size estimate was 
combined using a random effects model according to the method of DerSimonian & Laird.26  
RESULTS 
Search results and study characteristics 
The search strategy yielded 4,123 results, which after de-duplication from the multiple 
databases resulted in 1,397 unique studies. Initial title screening by AD excluded 813 studies, 
with the remaining 584 studies assessed for eligibility by three authors (AD, SS, TK). Abstract 
screening excluded a further 549 studies, leaving 35 for full-text review. Full-text review 
excluded a further 25, leaving 10 eligible studies included in this systematic review and meta-
analysis. Figure 1 details the results of the systematic search. 
Across the 10 studies, 21 BoE (including nicotine) were reported. Biomarkers were collected 
throughout the intervention period via 24-hour urine samples, and daily blood samples in the 
six studies that had a confinement period, and at set points in those with an ambulatory period. 
To limit the number of biomarkers being assessed and to ensure meaningful outcomes through 
a sufficient quantity of data, only biomarkers that were reported in at least eight of the ten 
eligible studies were analysed. Twelve biomarkers met this criteria: 1-hydroxypyrene (1-OHP), 
2-aminoaphthalene (2-AN), 3-cyanoethylmercapturic acid (CEMA), 3-
hydroxypropylmercaptauric acid (3-HPMA), 4-aminobiphenyl (4-ABP), 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), carboxyhemoglobin (COHb), 
























(0-tol), s-phenylmercapturic acid (S-PMA), and total nicotine equivalents (TNeq). 
Supplementary Appendix 2 lists the 21 BoEs evaluated throughout the studies, their 
attributed HPHCs, and the 12 BoE that were eligible and assessed in this review (bolded).  
A total of 1,766 participants were involved in the 10 studies, which were conducted in Japan, 
Poland, or the USA. Table 1 details study characteristics and participant demographics. Most 
studies utilised a randomised controlled trial (RCT) design, except for one semi-RCT design.27 
Common participant exclusion criteria were: inadequate contraception, pregnant or 
breastfeeding, recent blood donation, current acute illness, recent non-cigarette tobacco use, 
planned to quit smoking within 12 months, or had abnormal laboratory tests (physical, medical, 
ECG, lung function, or laboratory panel). All studies had most or all of the authors employed 
by a tobacco manufacturer, and all studies were funded by these manufacturers. After baseline 
measurements, participants were allocated to continue smoking conventional cigarettes, 
exclusively use a HNB device, or be completely abstinent from nicotine products.  
Conventional cigarettes used were the smokers’ usual brand, except for two studies that 
provided cigarettes.27,32 HNB devices included the commercially available ‘glo’ and ‘IQOS’, 
as well as ‘precursor’ products, which includes devices still under development, and earlier 
device models which have been refined and are now commercially available. Nicotine quantity 
in the HNB devices ranged from 0.3mg to 1.21mg per stick/capsule. These devices all include 
a rechargeable battery-powered heating element and insert-able capsule or stick which contains 
processed tobacco leaf. Some also contain a nicotine-free liquid, which is heated (instead of 
the tobacco leaf) into a vapour which passes through the tobacco, drawing out the nicotine and 
flavours. After baseline measurements and allocation, the intervention period ran for 5 days in 
confinement in six studies,28-32,34 28 days in a residential setting in one study,27 5 days in 
confinement followed by 85 days ambulatory in two studies study,33,35 and a 6-month 
























both during confinement and in an ambulatory setting only had their confinement data 
analysed. Confinement involved physical restriction to the clinic for the duration of the 
intervention period, and supervised smoking only in smoking rooms during approved hours 
(6:30am to 11:00pm in most studies). HNB sticks/capsules and conventional cigarettes were 
provided one at a time upon participant request, with puffing topography (number of puffs, 
total puff volume, and puff duration) recorded throughout the confinement period in most of 
the studies.27-31,33,34  
Quality Appraisal 
The JBI quality appraisal checklist found all ten studies as being of moderate quality, scoring 
8 or 9 out of 13. Four of the checklist items were commonly unmet by these studies, due to 
study design and being unable to blind participants or researchers (checklist items 2, 4, 5, and 
6). This lack of blinding was due to the obvious and unavoidable differences in the 
interventions used between the different arms of these studies (conventional cigarette, HNB, 
or abstinence). A lack of clarity on the method of randomisation used (checklist item 1) was a 
further issue with some of the studies. An additional consideration relating to reporting bias, is 
that all ten studies had one or more of the authors employed by PMI, BAT, or Japan Tobacco 
Inc., with these companies also funding the research. Due to the small number of studies 
available and the unavoidable issues arising from trial design (relating to blinding), their 
inclusion in the analysis was necessary.  
Product use and biomarkers of exposure (BoE) 
Biomarker data were extracted from the full analysis set for most studies, except for two that 
used the per protocol set.33,35 Total daily use of HNB and conventional cigarette use was 
unrestricted in all but two studies, one which restricted both HNB and conventional cigarette 
use to 125% of usual daily cigarette consumption,32 and one which restricted conventional 
























In six unrestricted-use studies, the total number of HNB capsules/sticks used were generally 
comparable to the number of conventional cigarettes. However, total puff volume, number of 
puffs, and puff duration were increased for HNB devices compared to conventional cigarettes 
in four of these studies,27,28,30,31 and comparable in the remaining two studies.29,33 In the four 
studies with different puffing behaviours, total puff volume increased by between 5-27%, 
number of puffs by 19-40%, and puff duration by approximately 33%.27,28,30,31 In the study 
which strictly limited consumption of conventional cigarettes (within 10% of normal use), total 
puff volume increased by nearly 200%, 30% increased puff duration, and 50% increased puff 
number for HNB participants.34 
Despite the increases in HNB use in these studies, the levels of all 12 BoEs analysed in this 
meta-analysis were significantly lower in the HNB participants compared to those assigned to 
conventional cigarettes. Table 2 outlines the effect sizes of the 12 BoE for the comparisons 
between the intervention and control groups, in descending order of effect size for HNB versus 
conventional cigarettes. Figure 2 illustrates (via forest plot) these effect sizes for each BoE, 
with the full set of 24 forest plots available in Supplementary Appendix 3. The most 
significant reductions between th se two intervention groups were seen for 2-aminoaphthalene 
(2-AN), carboxyhemoglobin (COHb), 4-aminobiphenyl (4-ABP), and 4-
cyanoethylmercapturic acid (CEMA), all with negative effect sizes (standard deviations) of 1.2 
or greater. Total nicotine equivalent (TNeq) exposure was the BoE least different between the 
two groups. In comparison to the abstinence group, the levels of 8 of 12 BoEs for HNB 
participants were not statistically different, whereas the BoEs 3-hydroxypropylmercaptauric 
acid (3-HPMA), N-nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol 
(NNAL), and TNeq were significantly higher in the HNB participants. TNeq had the greatest 
difference between the two groups, with a positive effect size of 1.91, whereas 3-HPMA, NNN, 

























Potential modified risk tobacco products such as the ‘IQOS’ and ‘glo’ HNB devices have been 
developed by tobacco manufacturers in response to the growing dissent for conventional 
cigarettes. Manufacturers claim these devices provide an alternative source of nicotine with 
significantly reduced risk to users. This study aimed to evaluate these claims relating to the 
relative safety of HNB products compared to conventional cigarettes. The analyses conducted 
in this study support these claims, with the levels of all 12 BoEs evaluated being significantly 
lower in the HNB participants compared to the conventional cigarette participants. These 
reductions were apparent even with changes in puffing topography, including increased puff 
volume, puff duration, and number of puffs in those assigned to HNB devices compared to 
conventional cigarettes. In addition, levels of 8 of the 12 BoEs in HNB participants were not 
significantly different to smoking abstinence, indicating that although they may have improved 
safety over conventional cigarettes, the complete safety of HNB devices cannot be assured. 
As described by Murphy et al (2017), arbitrary placement on the risk continuum can be rectified 
by supporting science that allows accurate placement and comparison of the relative safety of 
the various tobacco products available.38 It is therefore necessary to distinguish different 
potential modified risk tobacco products along this continuum, such as e-cigarettes and HNB 
devices, as well as the differences between individual HNB devices.17,38 A recent review by 
Simonavicius et al (2018) assessed HNB emissions, as well as BoEs from many of the RCTs 
analysed in the current study stated, “evidence on HNB second-hand emissions suggested that 
HNB exposes users and bystanders to substantially lower but measurable levels of particulate 
matter and HPHC”.18 The authors also described differences in potential harm between 
individual HNB devices, with the aerosol of IQOS containing the highest proportional levels 
of nicotine and HPHCs, followed by glo, and then the iFuse device.18 These findings indicate 
























that individual HNB devices may also have different relative levels of safety. Similar to the 
findings of the current study, Simonavicius and colleagues also noted that HNB participants 
utilised compensatory puffing techniques, which may have resulted from lower nicotine 
exposure per puff with HNB devices.18 Furthermore, the potential public health benefits of 
HNB devices may be marred by dual use of these devices with conventional cigarettes, which 
has been the case to some extent for electronic cigarettes.39 Dual use would substantially reduce 
the health benefits of HNB devices by inhibiting the reduction in biomarkers of exposure. A 
concern related to this finding is the issue of addiction development itself, and the potential for 
the normalisation of smoking behaviours using devices that are marketed as ‘reduced risk’.40 
Health risk estimation can be achieved through the linking of individual BoEs to specific health 
consequences resulting from exposure, to inform on the relative risk of different tobacco 
products. Both COHb and 2-AN had the greatest reductions in exposure between HNB devices 
and conventional cigarettes. COHb levels are elevated several times above normal in tobacco 
smokers,41 with the resulting displacement of oxygen from hemoglobin leading to headaches, 
dizziness, and gastrointestinal upset, but also increasing the risk of atherosclerosis.42,43 
Similarly, 2-AN and 4-ABP are known carcinogens suspected to contribute to bladder 
cancer).44,45 Replacement of conventional cigarettes with a HNB device may therefore confer 
some level of protection against these health consequences that are often attributed to smoking. 
However, NNN and NNAL were elevated in comparison to abstinence, and are linked to 
respiratory and pancreatic cancers, signifying continued safety concerns.45,46 Quantifying 
measurable outcomes such as BoEs contribute to the goal of assessing relative safety, and allow 
substantiation of claims for reduced potential for harm of HNB devices. To date, two small 
independent studies have evaluated comparative levels of a single BoE (carbon monoxide) 
























Based on the findings of the current study, further research is required to understand to what 
degree these ‘potential modified risk tobacco products’ differ in their delivery of nicotine and 
HPHCs, and the resulting levels of key BoEs in smokers and close-contact non-smokers. This 
includes the potential for second-hand smoke from HNB devices to raise BoE levels in non-
smokers. Transparent and standardised independent research utilising clear protocols is 
required, to allow the comparison and interpretation of multiple, large datasets relating to the 
safety of these emerging tobacco products. Similar recommendations were made recently by 
Hendlin et al. (2019) in a systematic review of financial conflicts of interest and harm 
reduction.49 Post-marketing surveillance of the spread and uptake of HNB devices is also 
needed to identify key population groups exposed to these devices such as adolescents, who 
may have altered pharmacokinetic profiles for HPHCs compared to the adult participants in 
this review. Adverse event data was also minimal in these studies due to the short duration of 
exposure, and long-term safety data would need to include comparative adverse event profiles 
between HNB and conventional tobacco products. 
Limitations 
There are limitations within this review as well as the eligible studies to consider when 
interpreting and applying these findings. Most notable is the involvement of the tobacco 
industry in the each of the studies included in this review, with author affiliations and funding 
issues introducing concerns relating to reporting bias.50-52 An additional consideration is that 
most studies had a short duration of exposure to the intervention materials. Confinement studies 
such as these are more informative and reliable than ambulatory studies, through having more 
control on participant exposure, though prevent an assessment of the long-term effects of HNB 
devices on BoEs. Confinement may have also affected participants’ urge to smoke through a 
reduction in their normal environmental cues, affecting the generalisability of these results to 
























In addition, there was a limited range of BoEs analysed due to inconsistency in the reporting 
of BoEs within the individual studies, preventing a more complete estimation of comparative 
levels of harm between HNBs and conventional cigarettes. Most of the studies were conducted 
in either Poland or Japan, which may confound the results due to metabolic differences between 
these populations and those from other countries and ethnicities. Precursor products in this 
review were in some cases not marketed, and with further development led to reductions in 
toxicant exposure and an underestimation of their total comparative safety to conventional 
cigarettes. Finally, the moderate quality of the studies identified through the quality appraisal 
tool (largely related to the unavoidable lack of blinding) requires that the results be interpreted 
and applied with caution.  
CONCLUSIONS 
Heat-not-burn devices such as ‘IQOS’ and ‘glo’ are marketed as ‘reduced risk’ tobacco 
products, and are claimed to reduce harm to smokers compared to conventional cigarettes. This 
review supports these claims, with all 12 BoEs that were analysed being significantly lower in 
the HNB participants compared to those using conventional cigarettes. These BoE reductions 
were greatest for several known carcinogens, including COHb, 2-AN, 4-ABP, and CEMA, 
indicating the potential for significantly reduced harm when using HNB devices in comparison 
to conventional cigarettes. In addition, levels of 8 of the 12 BoEs were statistically equivalent 
between the HNB and abstinence participants, though the levels of some carcinogenic BoEs 
were significantly increased. HNB devices therefore may have a role in harm reduction though 
should not be considered as wholly safe. The strong involvement of tobacco manufacturers in 
these studies demonstrates the need for caution in interpreting these findings, and the need for 
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Figure 2. The forest plot illustrating the post-exposure mean differences in 2-AN between 
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* Total number of participants completing the study, and the number of participants assigned 
























& JTI: Japan Tobacco Inc., PMI: Philip Morris International, BAT: British American 
Tobacco 
# JBI: Joanna Briggs Institute quality checklist, which had a maximum score of 13 
CPD: Cigarettes Per Day  ^ Haziza 2016b published a second article including data 

























Table 2. BoE effect sizes (standard deviations) and p-values for the HNB group versus 
conventional cigarette (CC) and Abstinence (Abs) groups. 
Biomarker of Exposure (BoE) Comparison 
Effect Size (SD) 




HNB vs. CC -1.77 (-2.07, -1.46) < 0.001 
HNB vs. Abs -0.08 (-0.26, 0.09) 0.367 
Carboxyhemoglobin 
(CoHB) 
HNB vs. CC -1.72 (-2.48, -0.97) < 0.001 
HNB vs. Abs 0.14 (-0.08, 0.37) 0.213 
4-aminobiphenyl  
(4-ABP) 
HNB vs. CC -1.53 (-1.76, -1.30) < 0.001 
HNB vs. Abs -0.04 (-0.22, 0.13) 0.639 
2-cyanoethylmercapturic acid 
(CEMA) 
HNB vs. CC -1.38 (-1.79, -0.98) < 0.001 
HNB vs. Abs -0.04 (-0.19, 0.11) 0.640 
3-hydroxypropylmercaptapuric acid  
(3-HPMA) 
HNB vs. CC -1.22 (-1.63, -0.82) < 0.001 
HNB vs. Abs 0.21 (0.02, 0.40) 0.027 
1-hydroxypyrene  
(1-OHP) 
HNB vs. CC -1.17 (-1.53, -0.80) < 0.001 
HNB vs. Abs -0.08 (-0.21, 0.05) 0.233 
S-phenylmercapturic acid 
(S-PMA) 
HNB vs. CC -1.14 (-1.35, -0.94) < 0.001 
HNB vs. Abs -0.10 (-0.28, 0.08) 0.275 
o-toluidine 
(o-tol) 
HNB vs. CC -1.03 (-1.25, -0.80) < 0.001 
HNB vs. Abs -0.00 (-0.16, 0.16) 0.988 
monohydroxybutenyl-mercapturic 
acid (MHBMA) 
HNB vs. CC -0.93 (-1.21, -0.66) < 0.001 
HNB vs. Abs -0.14 (-0.35, 0.07) 0.192 
N-nitrosonornicotine  
(NNN) 
HNB vs. CC -0.82 (-1.15, -0.48) < 0.001 
HNB vs. Abs 0.22 (0.01, 0.43) 0.041 
4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanol (NNAL) 
HNB vs. CC -0.65 (-0.82, -0.48) < 0.001 
HNB vs. Abs 0.11 (0.03, 0.18) 0.005 
Total Nicotine Equivalents 
(TNeq) 
HNB vs. CC -0.37 (-0.70, -0.05) 0.023 
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